The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Current Clinical Pharmacology · 01.05.2008 · 3 (2) · 132-143
DOI: 10.2174/157488408784293705 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Clinical Pharmacology, erschienen am 01.05.2008. Verfasst von Jeanine M Roodhart und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology (F02.126), University Medical Center Utrecht, Utrecht, The Netherlands. Die Arbeit wurde bisher 179-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology (F02.126), University Medical Center Utrecht, Utrecht, The Netherlands.
Zitieren
APA
Roodhart, J. M., Langenberg, M. H., Witteveen, E., & Voest, E. E. (2008). The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway. Current Clinical Pharmacology, 3(2), 132-143. https://doi.org/10.2174/157488408784293705
Vancouver
Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway. Current Clinical Pharmacology. 2008;3(2):132-143. doi:10.2174/157488408784293705
BibTeX
@article{Roodhart2008,
author = {Roodhart, Jeanine M and Langenberg, Marlies H and Witteveen, Els and Voest, Emile E},
title = {The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway},
journal = {Current Clinical Pharmacology},
year = {2008},
volume = {3},
number = {2},
pages = {132--143},
doi = {10.2174/157488408784293705}
}
EUVIMED